SAB BIOTHERAPEUTICS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price
SAB BIOTHERAPEUTICS, INC. (SABS) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price of $7.86 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2026-03-31 was $9.76, a 43.32% decline year-over-year.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2025-03-31 was $17.22, a 66.30% decline year-over-year.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2024-03-31 was $51.10, a 880.81% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2023-03-31 was $5.21.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2025 was $19.56, a 85.58% increase from fiscal 2024.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2024 was $10.54, a 46.06% decline from fiscal 2023.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2023 was $19.54, a 293.16% increase from fiscal 2022.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2022 was $4.97.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.86 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $9.76 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | $19.56 10-K · filed 2026-03-09 | |||
| 2025-09-30 | $24.65 10-Q · filed 2025-11-14 | |||
| 2025-06-30 | $21.68 10-Q · filed 2025-08-07 | |||
| 2025-03-31 | $17.22 10-Q · filed 2025-05-09 | |||
| 2024-12-31 | $10.54 10-K · filed 2025-03-31 | |||
| 2024-09-30 | $15.28 10-Q · filed 2024-11-06 | |||
| 2024-06-30 | $44.28 10-Q · filed 2024-08-08 | |||
| 2024-03-31 | $51.10 10-Q · filed 2024-05-20 | |||
| 2023-12-31 | $19.54 10-K · filed 2024-03-29 | |||
| 2023-09-30 | $2.06 10-Q · filed 2023-11-13 | |||
| 2023-06-30 | $4.90 10-Q · filed 2023-08-21 | |||
| 2023-03-31 | $5.21 10-Q · filed 2023-05-15 | |||
| 2022-12-31 | $4.97 10-K · filed 2023-04-14 | |||
| 2022-09-30 | $4.97 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |